Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Sipuleucel-T Stories

2012-04-17 02:27:57

SAN FRANCISCO, April 17, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that Mitchell H. Gold, M.D., has joined its board of directors. Dr. Gold is the executive chairman of Dendreon Corporation (Nasdaq: DNDN), the Seattle-based biotechnology company that discovered, developed, and launched a new class of therapies called...

2011-10-17 11:40:00

SEATTLE, Oct. 17, 2011 /PRNewswire/ - Christopher Henney, Chairman of the Board of Oncothyreon Inc. (Nasdaq: ONTY) and of Anthera Pharmaceuticals (Nasdaq: ANTH) and Vice Chairman of the Board of Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), received this year's Hall of Fame - special recognition of outstanding individual contributions award at the annual Biotech CEO Meeting at Laguna Beach. Henney, the co founder of Immunex, ICOS and Dendreon corporations was recognized for his...

2011-09-30 09:00:00

THE WOODLANDS, Texas, Sept. 30, 2011 /PRNewswire/ -- David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. (Logo: http://photos.prnewswire.com/prnh/20110916/MM70140LOGO)...

Cancer Costs Is Spiraling Out Of Control
2011-09-26 11:41:15

   Researchers say that the cost of treating cancer is spiraling out of control and becoming unaffordable in many developed countries. The international team of researchers say there is a "culture of excess" with insufficient evidence about the "value" of new treatments and technologies. "The cancer community needs to take responsibility and not accept a sub-standard evidence base and an ethos of very small benefit at whatever cost," said a report commissioned by the Lancet...

2011-08-10 07:46:00

BETHESDA, Md., Aug. 10, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) reminded markets, in response to recent investor concerns about Dendreon's Provenge immune therapy, that NWBT's DCVax® immune therapies for a broad range of cancers (including prostate, brain, ovarian and others) hold the promise, based on available data to date, of being cost effective and priced below other immune therapies while still providing substantial profit margins for the...

2011-08-05 15:45:00

SEATTLE, Aug. 5, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the Canaccord Genuity Growth Conference in Boston, MA on August 10 at 5:00 PM EDT. The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the...

2011-08-03 15:01:00

SEATTLE, Aug. 3, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the second quarter ended June 30, 2011. Net revenue for the quarter ended June 30, 2011 was $49.6 million compared to $2.8 million for the quarter ended June 30, 2010. This included a $1.9 million reserve for estimated rebates and chargebacks associated with either Medicaid patients or other pricing discounts offered pursuant to mandatory federal and state government programs. Gross...

2011-07-18 14:00:00

NEW YORK, July 18, 2011 /PRNewswire/ -- Just one year after the FDA approved Provenge, an immunotherapy for treating advanced prostate cancer, Medicare announced that they will continue to pay in full for Provenge when used in accordance with label indications. Provenge, unlike traditional hormone or chemotherapy treatments, uses a patient's own cells to fight the cancer, thereby extending the life of the patient. Dr. David Samadi, Vice Chairman, Department of Urology, and Chief Robotics...

2011-07-08 07:30:00

SEATTLE, July 8, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Wednesday, August 3, 2011 at 4:30 p.m. ET to review the second quarter 2011 financial results. Access to the discussion may be obtained as follows: Time: 4:30 PM ET / 1:30 PM PT Date: August 3, 2011 1-877-548-9590 (domestic) or Dial-in: +1-720-545-0037 (international); conference pass code:...

2011-06-30 15:47:00

SEATTLE, June 30, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC). The U.S. Food and Drug Administration (FDA) approved the Los Angeles immunotherapy manufacturing...